Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma

Inclusion Criteria:

• Histologically confirmed solid tumor or lymphoma
• Refractory to standard therapy or no standard therapy exists
• Measurable or evaluable disease

• No active brain metastases

  • Previously treated brain metastases allowed provided the patient is not currently receiving corticosteroids
  • Primary brain neoplasms allowed, regardless of corticosteroid use
• Performance status - Karnofsky 70-100%
• WBC ≥ 3,000/mm^3
• Absolute neutrophil count ≥ 1,500/mm^3
• Platelet count ≥ 100,000/mm^3
• No life-threatening bleeding diathesis within the past 6 months
• Bilirubin normal (unless due to Gilbert's syndrome)
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia
• No prior proven gastric or duodenal ulcer
• No clinically significant gastrointestinal blood loss within the past 6 weeks
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No prior CNS hemorrhage
• No psychiatric illness or social situation that would preclude study compliance
• No other concurrent uncontrolled illness
• No ongoing or active infection
• No prior cilengitide (EMD 121974)
• No other concurrent biologic therapy
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• No concurrent chemotherapy
• See Disease Characteristics
• More than 4 weeks since prior radiotherapy and recovered
• No concurrent palliative radiotherapy
• No other concurrent anticancer agents or therapies intended to treat the malignancy
• No other concurrent investigational agents

• No concurrent anticoagulation therapy that increases INR or aPTT above the normal range

  • Line prophylaxis allowed